Results for "Agilent"

Agilent Introduces the Cary 635 FTIR Spectrometer  Morningstar

Agilent Technologies’ chief executive detailed the company’s third-quarter financial performance and provided updates on its strategic direction within the life sciences sector. Management highlighted key operational metrics and future growth catalysts during the earnings discussion.

The life sciences company reported 7.3% revenue growth for its third quarter, surpassing analyst expectations and expanding profit margins while lifting its full-year guidance.

Several US companies, including WisdomTree, DexCom, and Agilent Technologies, saw their stock prices hit new 52-week highs. Pulse Biosciences, Heartflow Inc, and Aveanna Healthcare also reached all-time high stock values.

Agilent Technologies is expanding its presence in oncology diagnostics. The article analyzes the company's growth prospects in this sector.

The Madison Large Cap Fund has chosen to sell its shares in Starbucks (SBUX) but is maintaining its position on Agilent Technologies (A) despite concerns about AI. The fund's decisions reflect its investment strategy in the current market.

Agilent Technologies (A) experienced a decline in its stock value during the first quarter, attributed to market speculation regarding a potential acquisition of QIAGEN.

Agilent Technologies (A) continued its positive performance, extending its winning streak on the back of a reported 58% increase in profits.

The transcript for Agilent's second-quarter 2026 earnings call has been released, providing details on the company's financial performance and outlook.

Wall Street analysts have released their latest research calls, with FedEx receiving an upgrade while Dollar General was downgraded. Other companies like Agilent, GE Aerospace, and Hershey also saw updated ratings.

These articles present individual analyses for a range of public companies, each assessing whether their respective stocks represent a good investment opportunity for potential buyers. The reports delve into the financial health and market position of various firms.

Citi has highlighted Agilent Technologies while simultaneously cutting its price target for Icon PLC, indicating varied outlooks for companies in the finance sector.

Agilent Technologies has announced the acquisition of Biocare Medical, a medical instruments manufacturer, for $950 million. This strategic move aims to expand Agilent's portfolio in the medical diagnostics sector.

Agilent has increased its fiscal 2026 EPS guidance, even as its first-quarter results fell short of expectations.

Wall Street analysts have provided target prices and ratings for O'Reilly Automotive stock and Agilent Technologies stock, offering insights into their market performance and future outlook.

Scientific instrument manufacturer Agilent Technologies shared its third-quarter 2026 earnings, noting steady performance across life sciences and applied chemical markets.

Agilent Technologies updated its full-year 2026 financial projections, citing improved market conditions and a return to 9% growth in China.

Agilent Technologies achieved a Non-GAAP EPS of $1.62 and revenue of $1.88 billion, outperforming market estimates thanks to steady instrument sales and laboratory solutions demand.

The article discusses the target prices set by Wall Street analysts for Agilent Technologies stock, providing insights into their expectations for the company's performance.

An assessment explores whether Agilent Technologies, Inc. (A) stock is positioned for growth as trends within the life sciences sector begin to stabilize, potentially offering new opportunities.

An analysis examines whether Agilent Technologies stock is outperforming the Nasdaq index.

Jim Cramer expressed his view that there might be an opportunity in Agilent stock and that Ciena has ample room for growth. He offered these insights as part of his ongoing market commentary.

Agilent Technologies has received an upgrade from Bank of America, citing the company's impressive performance in its fiscal second quarter and its overall growth trajectory. The upgrade reflects confidence in Agilent's financial health and market position.

Agilent Technologies announced better-than-expected Q2 earnings, with non-GAAP EPS of $1.49 and revenue of $1.83 billion, both surpassing analyst estimates. The company also adjusted its fiscal 2026 guidance.

Several companies, including Freightos, Champion Homes, and Aurora Mobile, have released their Q1 or Q4 2026 earnings reports. Some companies, like VNET and JOYY, missed top-line and bottom-line estimates, while others like FinVolution Group reaffirmed their full-year outlooks.

Agilent Technologies (A) has announced its intention to acquire Biocare Medical for $950 million, a move expected to expand its presence in the life sciences and diagnostics market.

Goldman Sachs has lowered its target for Agilent (A) while maintaining long-term confidence in the company's growth prospects.

Agilent Technologies reported a 320 basis point increase in non-GAAP margins, prompting investor analysis on the sustainability and repeatability of this profitability surge.

Agilent Technologies shared its third-quarter financial performance, outlining key metrics and business developments discussed during the earnings briefing.

As the quarterly earnings season progresses, investors are closely monitoring CrowdStrike’s results for revenue acceleration while turning their attention to Agilent’s upcoming report for margin guidance.

Agilent Technologies (Agnt) has provided guidance for its third-quarter revenue, expecting it to fall between $1.35 billion and $1.45 billion, while also tightening its 2026 adjusted EBITDA forecast to $50 million-$60 million.

Agilent Technologies, Inc. (A) has received a 'Neutral' rating and a $150 price target from Piper Sandler in its initial coverage.

Agilent has secured expanded approval for its diagnostic test, which is designed to identify potential patients for Keytruda, a prominent cancer immunotherapy drug.

Analysts have released conflicting sentiments on several consumer cyclical companies, including Citi Trends, Caesars Entertainment, and Yeti Holdings. Additionally, insights were provided for healthcare companies like Phreesia, Agilent, and Pfizer, and other consumer cyclical firms such as Tesla and BMW.

Agilent Technologies has projected its fiscal year 2026 earnings per share to be between $6.00 and $6.10, attributing an 85 basis point operating margin expansion to its Ignite program.

RBC has reiterated its 'outperform' rating for Agilent and set a target price of $153, based on the company's growth outlook.

Agilent Technologies announced a quarterly dividend of $0.255 per share, while Ingredion Incorporated declared a quarterly dividend of $0.82 per share. Both companies made their respective dividend declarations.

Emerald Growth Equity Strategy has reportedly increased its stake in Nvidia (NVDA), indicating a strategic investment move by the equity firm.

An article analyzes whether Agilent Technologies stock is underperforming the S&P 500, providing insights for investors.

Agilent Technologies announced its plan to acquire Biocare Medical for $950 million, a move aimed at expanding its pathology portfolio.

Agilent Technologies shared key highlights from its first-quarter earnings call, detailing its financial results and business outlook for the period.

Agilent Technologies, Inc. (A) is sparking confidence among investors and stakeholders following its latest approvals.